Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants

Exclusion Criteria

• •1. Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, symptomatic inflammatory bowel disease or ulcerative colitis, or partial or complete bowel obstruction
• •2. On a Bruton's tyrosine kinase (BTK) inhibitor
• •3. Planned or concurrent use of a host modifiers/immune-based therapies or anti-CD20 monoclonal antibody treatment
• •4. Participants with prior of current hematologic malignancy or solid tumor malignancy with treatment within 6 months prior to study entry